JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Predicting pathologic fracture risk in the management of metastatic bone defects.

Guidelines for the prediction of pathologic fracture would facilitate the management of patients with metastatic bone defects. Unfortunately, existing clinical guidelines have not been validated, often run counter to engineering practice, and do not accurately predict the risk of fracture for many patients. To serve as a basis for improved guidelines, a factor of risk for a pathologic fracture is defined as the load applied to a bone divided by the load at which the bone fails. Failure loads for bones with metastatic defects have been measured in vitro, and depend on defect geometry, bone properties, and the type of loading. For a diaphyseal defect that destroys 50% of the cortex, strength reductions of between 60% and 90% can occur. The load-bearing capacity of a long bone with a diaphyseal defect also can be predicted using computer models if the geometry of the defect and properties of surrounding bone are known. Similarly, new methods that apply basic engineering principles to computed tomography data allow prediction of the load-bearing capacity of vertebrae with simulated defects. By contrast, the data presented here suggest that by using plane radiographs or computed tomographic (CT) examinations, experienced orthopaedic surgeons cannot accurately estimate the strength reductions or load-bearing capacity for proximal femurs with intertrochanteric defects. By combining new methods to predict the load-bearing capacity with estimated loads for activities of daily living, it is possible to calculate a factor of risk for pathologic fractures.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app